

Synthesis and biological evaluation of new 4-thiazolidinone derivatives of flurbiprofen

Pelin Süzgün ¹, Sevil Şenkardeş ^{1*} Merve Gürboğa ²,

Özlem Bingöl Özakpınar ² and Ş. Güniz Küçükgül ³

¹Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Marmara University, 34854, Istanbul, Türkiye

²Department of Pharmaceutical Biochemistry, Faculty of Pharmacy, Marmara University, 34854, Istanbul, Türkiye

³Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Fenerbahçe University, 34758, Istanbul, Türkiye

(Received December 05, 2022; Revised March 02, 2023; Accepted March 04, 2023)

Abstract: In this study, the synthesis and characterization of 2-(2-fluorobiphenyl-4-yl)-*N'*-(substituted methylene)propanehydrazides (**3a-s**) and 2-(2-fluoro-[1,1'-biphenyl]-4-yl)-*N*-(5-methyl-2-(substituted aryl)-4-oxothiazolidin-3-yl)propanamides (**4a-s**) are described and also the antiproliferative effect of the compounds on HT-29, HeLa, A549 and MCF-7 cancer cell lines is investigated. Additionally, mouse embryonic fibroblast cells NIH3T3 were also evaluated to determine the selectivity. The results showed that the identified compounds did not cause any toxicity against NIH3T3 cell line. Moreover, *N*-(2-(3,5-Bis(trifluoromethyl)phenyl)-5-methyl-4-oxothiazolidin-3-yl)-2-(2-fluoro-[1,1'-biphenyl]-4-yl)propanamide (**4h**) had the most growth inhibitory effect (55.97% inhibition) on HT-29 colorectal adenocarcinoma cell line. The results obtained from the study show that the compound **4h**, which has no cytotoxic effect on normal cells, may be an alternative in the treatment of colon cancer.

Keywords: Hydrazone; 4-thiazolidinone; MTT; antiproliferative activity; flurbiprofen. ©2023 ACG Publication. All right reserved.

1. Introduction

Cancer, characterised by uncontrolled and pathological proliferation of abnormal cells, is the second main reason of death after cardiovascular diseases in developing and advanced countries.¹ Even though there are numerous techniques such as chemotherapy and radiotherapy, toxic effect and drug resistance restriction the success effects most of the time.

4-Thiazolidinone scaffold is an advantageous molecular modification for indicating chemical capabilities in biologically active compounds due to various activities like anticancer,²⁻⁴ antimycobacterial,⁵ antiviral,^{6,7} antibacterial,^{8,9} analgesic¹⁰ and antidiabetic¹¹ that are even found in FDA-approved drugs (Figure 1).

Hydrazones have received remarkable interest due to their broad spectrum and metabolic profile.¹²⁻¹⁴ These structures have been exhibited a wide spectrum of biological effects including anticancer effects.¹⁵⁻²³

Flurbiprofen is a nonsteroidal anti-inflammatory drug (NSAID) and some researches have reported that this drug and its structural derivatives exhibit anticancer activities against colorectal, breast, lung, and cervical cancer cell lines.²⁴⁻²⁷ In this context, our research group reported the synthesis

* Corresponding author: E-mail: sevil.aydin@marmara.edu.tr Phone: +90-216-777 52 00.

Synthesis and anticancer activity of flurbiprofen derivatives

of 2-(2-fluorobiphenyl-4-yl)-*N'*-[(substituted phenyl/5-nitro-2-furyl)methylene]propane hydrazides and 2-(2-fluoro-4-biphenyl)-*N*-(2-substituted-4-oxo-1,3-thiazolidine-3-yl)propanamides via flurbiprofen and evaluated their anticancer activities.²⁸ However, there was no literature on the synthesis and antiproliferative potential of 5-methyl-4-thiazolidinones derived from flurbiprofen. We tried to replace the -H with -CH₃ on the 4-thiazolidinone ring and reported the findings of their biological activities.

Regarding this point together with the aim of exploring new cytotoxic agents, we synthesized a series of hydrazone-hydrazone and 5-methyl-4-thiazolidinone derivatives starting from flurbiprofen and evaluated the effects of these compounds on HT-29 (colorectal adenocarcinoma), HeLa (human cervical carcinoma), A549 (human lung adenocarcinoma), MCF-7 (human breast cancer) cell lines and NIH3T3 (mouse embryonic fibroblast) cell line at 10 μM concentration.




Figure 1. Some marketed drugs containing 4-thiazolidinone ring

2. Experimental

2.1. Chemical Material and Apparatus

All the reagents used were analytical reagent grade. Melting points were determined on a Thermo Scientific 9300 apparatus and are uncorrected. FTIR spectra were recorded on a Shimadzu FTIR 8400S spectrometer and frequencies are expressed in cm⁻¹. NMR spectra were recorded on a BRUKER AVANCE 300 spectrometer operating 300.00 MHz (¹H) and 75.0 MHz (¹³C) in deuterated solvent. Elemental analyses were determined on CHNS-932 (LECO) analyzer.

2.2. Chemistry

2.2.1. General procedure for the Preparation 2-(2-fluorobiphenyl-4-yl)-*N'*-[(substituted methylene]propanehydrazides (3a-s)

The methyl 2-(2-fluorobiphenyl-4-yl)propanoate (**1**) and compound **2** were prepared as per the reported method.^{29, 30} A mixture of 2-(2-fluoro[1,1'-biphenyl]-4-yl)propanehydrazide (**2**) (1.0 eq.) and various aldehydes (1.0 eq.) in ethanol were refluxed in the presence of glacial acetic acid for 3-6 h. After cooling to the room temperature, the precipitate was filtered, washed with water, dried, and recrystallized from ethanol.

N'-[(4-Cyanophenyl)methylidene]-2-(2-fluoro[1,1'-biphenyl]-4-yl)propanehydrazide (**3a**): White solid. M.p. 163-164 °C. Yield 85%. IR ν_{\max} (cm⁻¹): 3184 (N-H), 2236 (C≡N), 1661 (C=O), 1626 (C=N); ¹H-NMR (DMSO-*d*₆, 300 MHz) δ (ppm): 1.43 and 1.46 (2d, 3H, *J*=6.9 Hz, CH₃), 3.81 and 4.79 (2q, 1H, *J*=6.9 Hz, CH-CH₃), 7.28-7.91 (m, 12H, Ar-H), 8.00 and 8.28 (2s, 1H, CH=N), 11.64 and 11.84

(2s, 1H, NH). ^{13}C -NMR (75 MHz) (DMSO- d_6 /TMS) δ ppm: 18.71, 44.01, 112.20, 115.49, 119.15, 124.46, 126.90, 127.84, 108.24, 129.04, 129.18, 131.17, 133.21, 135.33, 139.15, 145.50, 157.70, 160.96, 169.99, 175.21. Anal. Calcd. for $\text{C}_{23}\text{H}_{18}\text{FN}_3\text{O}$: C, 74.38; H, 4.88; N, 11.31. Found: C, 74.66; H, 4.93; N, 11.31.

2-(2-Fluoro-[1,1'-biphenyl]-4-yl)-N'-(3-phenoxybenzylidene)propanehydrazide (3b): White solid. M.p. 144-145°C. Yield 80%. IR ν_{max} (cm^{-1}): 3188 (N-H), 1661 (C=O), 1643 (C=N); ^1H -NMR (DMSO- d_6 , 300 MHz) δ (ppm): 1.39 and 1.43 (2d, 3H, $J=6.9$ Hz, CH_3), 3.77 and 4.62 (2q, 1H, $J=6.9$ Hz, CH- CH_3), 7.03-7.52 (m, 17H, Ar-H), 7.92 and 8.20 (2s, 1H, CH=N), 11.43 and 11.64 (2s, 1H, NH). ^{13}C -NMR (75 MHz) (DMSO- d_6 /TMS) δ ppm: 18.82, 43.94, 115.26, 115.70, 119.41, 120.32, 120.68, 123.16, 124.30, 128.20, 129.07, 129.15, 130.64, 135.34, 136.66, 142.69, 143.81, 146.70, 156.64, 157.68, 160.95, 169.70, 174.81. Anal. Calcd. for $\text{C}_{23}\text{H}_{23}\text{FN}_2\text{O}_2$: C, 76.69; H, 5.26; N, 6.39. Found: C, 77.20; H, 5.20; N, 6.35.

2-(2-Fluoro-[1,1'-biphenyl]-4-yl)-N'-(3-(trifluoromethyl)benzylidene)propanehydrazide (3c): White solid. M.p. 194-195°C. Yield 91%. IR ν_{max} (cm^{-1}): 3192 (N-H), 1654 (C=O), 1622 (C=N); ^1H -NMR (DMSO- d_6 , 300 MHz) δ (ppm): 1.43 and 1.46 (2d, 3H, $J=7.2$ Hz, CH_3), 3.81 and 4.74 (2q, 1H, $J=6.9$ Hz, CH- CH_3), 7.25-7.99 (m, 12H, Ar-H), 8.02 and 8.31 (2s, 1H, CH=N), 11.43 and 11.64 (2s, 1H, NH). ^{13}C -NMR (75 MHz) (DMSO- d_6 /TMS) δ ppm: 18.89, 43.95, 115.50, 122.66, 123.52, 124.31, 126.27, 127.10, 128.18, 128.25, 129.10, 129.91, 130.33, 131.08, 135.34, 135.87, 141.75, 157.70, 169.94, 175.03. Anal. Calcd. for $\text{C}_{23}\text{H}_{18}\text{F}_4\text{N}_2\text{O}$: C, 66.66; H, 4.38; N, 6.76. Found: C, 67.24; H, 4.49; N, 6.75.

N'-(3-Bromobenzylidene)-2-(2-fluoro-[1,1'-biphenyl]-4-yl)propanehydrazide (3d): White solid. M.p. 148-149°C (lit. 147-148°C³⁰). Yield 87%. IR ν_{max} (cm^{-1}): 3186 (N-H), 1651 (C=O), 1624 (C=N); Anal. Calcd. for $\text{C}_{22}\text{H}_{18}\text{BrFN}_2\text{O} \cdot 1/3\text{H}_2\text{O}$: C, 61.27; H, 4.36; N, 6.50. Found: C, 61.62; H, 4.72; N, 6.25.

N'-(4-Bromobenzylidene)-2-(2-fluoro-[1,1'-biphenyl]-4-yl)propanehydrazide (3e): White solid. Yield 71%; M.p. 173-174°C; IR ν_{max} (cm^{-1}): 3176 (N-H), 1660 (C=O), 1610 (C=N); ^1H -NMR (DMSO- d_6 , 300 MHz) δ (ppm): 1.43 and 1.46 (2d, 3H, $J=6.9$ Hz, CH_3), 3.78 and 4.76 (2q, 1H, $J=6.9$ Hz, CH- CH_3), 7.26-7.65 (m, 12H, Ar-H), 7.94 and 8.20 (2s, 1H, CH=N), 11.47 and 11.68 (2s, 1H, NH). ^{13}C -NMR (75 MHz) (DMSO- d_6 /TMS) δ ppm: 18.74, 43.96, 124.58, 126.78, 127.07, 127.25, 128.19, 128.25, 129.13, 131.14, 132.29, 133.96, 135.35, 146.19, 157.69, 169.72, 174.93. Anal. Calcd. for $\text{C}_{22}\text{H}_{18}\text{BrFN}_2\text{O}$: C, 62.18; H, 4.27; N, 6.59. Found: C, 61.98; H, 4.46; N, 6.52.

N'-(Benzo[d][1,3]dioxol-4-ylmethylene)-2-(2-fluoro-[1,1'-biphenyl]-4-yl)propanehydrazide (3f): White solid. M.p. 190-192°C. Yield 91%. IR ν_{max} (cm^{-1}): 3182 (N-H), 1651 (C=O), 1610 (C=N); ^1H -NMR (DMSO- d_6 , 300 MHz) δ (ppm): 1.43 and 1.47 (2d, 3H, $J=6.9$ Hz, CH_3), 3.75 and 4.74 (2q, 1H, $J=6.9$ Hz, CH- CH_3), 6.10-6.12 (m, 2H, $-\text{CH}_2$), 6.85-7.44 (m, 11H, Ar-H), 8.03 and 8.32 (2s, 1H, CH=N), 11.45 and 11.65 (2s, 1H, NH). ^{13}C -NMR (75 MHz) (DMSO- d_6 /TMS) δ ppm: 18.62, 44.09, 102.00, 109.85, 115.26, 118.56, 124.41, 124.58, 126.77, 128.19, 129.07, 131.06, 135.37, 137.72, 144.20, 146.74, 157.66, 169.55, 174.81. Anal. Calcd. for $\text{C}_{23}\text{H}_{19}\text{FN}_2\text{O}_3$: C, 70.76; H, 4.91; N, 7.18. Found: C, 70.10; H, 5.21; N, 7.06.

N'-(2,6-Dichlorobenzylidene)-2-(2-fluoro-[1,1'-biphenyl]-4-yl)propanehydrazide (3g): White solid. M.p. 198-200°C. Yield 95%. IR ν_{max} (cm^{-1}): 3203 (N-H), 1653 (C=O), 1628 (C=N); ^1H -NMR (DMSO- d_6 , 300 MHz) δ (ppm): 1.43 and 1.46 (2d, 3H, $J=6.9$ Hz, CH_3), 3.79 and 4.67 (2q, 1H, $J=6.9$ Hz, CH- CH_3), 7.20-7.58 (m, 11H, Ar-H), 8.26 and 8.43 (2s, 1H, CH=N), 11.69 and 11.88 (2s, 1H, NH). Anal. Calcd. for $\text{C}_{22}\text{H}_{17}\text{Cl}_2\text{FN}_2\text{O}$: C, 63.63; H, 4.13; N, 6.75. Found: C, 64.21; H, 4.11; N, 6.73.

N'-(3,5-bis(trifluoromethyl)benzylidene)-2-(2-fluoro-[1,1'-biphenyl]-4-yl)propane hydrazide (3h): White solid. M.p. 130-131°C. Yield 91%. IR ν_{max} (cm^{-1}): 3182 (N-H), 1654 (C=O), 1622 (C=N); ^1H -NMR (DMSO- d_6 , 300 MHz) δ (ppm): 1.42 and 1.47 (2d, 3H, $J=6.9$ Hz, CH_3), 3.84 and 4.74 (2q, 1H, $J=6.9$ Hz, CH- CH_3), 7.23-8.45 (m, 11H, Ar-H), 8.13 and 8.38 (2s, 1H, CH=N), 11.77 and 12.00 (2s, 1H, NH). ^{13}C -NMR (75 MHz) (DMSO- d_6 /TMS) δ ppm: 19.05, 43.90, 115.29, 121.83, 124.09, 125.44,

Synthesis and anticancer activity of flurbiprofen derivatives

127.37, 128.27, 129.07, 131.00, 135.30, 137.56, 140.04, 144.04, 144.71, 170.21, 175.21. Anal. Calcd. for $C_{24}H_{17}F_7N_2O_1/2H_2O$: C, 58.66; H, 3.69; N, 5.70. Found: C, 58.86; H, 3.55; N, 5.66.

(2-(2-fluoro-[1,1'-biphenyl]-4-yl)-N'-(2-(trifluoromethoxy)benzylidene)propanehydrazide (**3i**): White solid. M.p. 134-136°C. Yield 88%. IR ν_{max} (cm^{-1}): 3194 (N-H), 1651 (C=O), 1622 (C=N); 1H -NMR (DMSO- d_6 , 300 MHz) δ (ppm): 1.06 (t, ethanol CH_3), 1.44 and 1.46 (2d, 3H, $J=6.9$ Hz, CH_3), 3.44 (m, ethanol CH_2), 3.77 and 4.77 (2q, 1H, $J=6.9$ Hz, CH- CH_3), 4.35 (t, ethanol OH), 7.26-7.85 (m, 12H, Ar-H), 7.99 and 8.25 (2s, 1H, CH=N), 11.50 and 11.70 (2s, 1H, NH). ^{13}C -NMR (75 MHz) (DMSO- d_6 /TMS) δ ppm: 18.79, 44.14, 115.82, 118.83, 122.29, 127.14, 127.77, 128.19, 128.49, 129.03, 131.86, 132.13, 135.34, 136.94, 140.28, 140.06, 147.13, 157.71, 169.82, 175.01. Anal. Calcd. for $C_{23}H_{18}F_4N_2O_2/1/2C_2H_5OH$: C, 63.57; H, 4.67; N, 6.18. Found: C, 63.60; H, 4.35; N, 6.46.

N'-[(4-Bromothiophen-2-yl)methylidene]-2-(2-fluoro[1,1'-biphenyl]-4-yl)propane hydrazide (**3j**): White solid. M.p. 203-204°C. Yield 79%. IR ν_{max} (cm^{-1}): 3167 (N-H), 1668 (C=O), 1635 (C=N); 1H -NMR (DMSO- d_6 , 300 MHz) δ (ppm): 1.41 and 1.45 (2d, 3H, $J=7.2$ Hz, CH_3), 3.75 and 4.58 (2q, 1H, $J=6.9$ Hz, CH- CH_3), 7.22-7.75 (m, 10H, Ar-H), 8.07 and 8.40 (2s, 1H, CH=N), 11.49 and 11.68 (2s, 1H, NH). ^{13}C -NMR (75 MHz) (DMSO- d_6 /TMS) δ ppm: 18.62, 43.99, 109.70, 115.25, 124.09, 126.06, 126.58, 128.26, 129.07, 131.17, 132.11, 132.82, 135.34, 136.96, 157.68, 169.68, 174.53. Anal. Calcd. for $C_{20}H_{16}BrFN_2OS$: C, 55.24; H, 3.66; N, 6.60. Found: C, 55.24; H, 3.65; N, 6.59.

N'-(5-Bromo-2-methoxybenzylidene)-2-(2-fluoro-[1,1'-biphenyl]-4-yl)propanehydrazide (**3k**): White solid. M.p. 199-200°C. Yield 89%. IR ν_{max} (cm^{-1}): 3194 (N-H), 1676 (C=O), 1645 (C=N); 1H -NMR (DMSO- d_6 , 300 MHz) δ (ppm): 1.42 and 1.45 (2d, 3H, $J=6.9$ Hz, CH_3), 3.71-4.75 (m, 4H, CH- CH_3 and $-OCH_3$), 7.23-7.87 (m, 11H, Ar-H), 8.20 and 8.48 (2s, 1H, CH=N), 11.44 and 11.71 (2s, 1H, NH). ^{13}C -NMR (75 MHz) (DMSO- d_6 /TMS) δ ppm: 18.87, 44.06, 56.56, 112.91, 114.85, 115.57, 124.34, 124.92, 128.26, 129.07, 131.12, 133.79, 134.05, 135.36, 137.48, 141.12, 157.13, 160.95, 169.62, 174.87. Anal. Calcd. for $C_{23}H_{20}BrFN_2O_2$: C, 60.67; H, 4.43; N, 6.15. Found: C, 61.05; H, 4.30; N, 6.29.

2-(2-Fluoro-[1,1'-biphenyl]-4-yl)-N'-(4-methoxy-3-nitrobenzylidene)propanehydrazide (**3l**): Off-white solid. M.p. 219-220°C. Yield 92%. IR ν_{max} (cm^{-1}): 3169 (N-H), 1668 (C=O), 1645 (C=N); 1H -NMR (DMSO- d_6 , 300 MHz) δ (ppm): 1.42 and 1.46 (2d, 3H, $J=7.2$ Hz, flur. CH_3), 3.79 and 4.76 (2q, 1H, $J=6.9$ Hz, CH- CH_3), 3.97 (s, 3H, $-OCH_3$), 7.41-8.21 (m, 12H, Ar-H and CH=N), 11.48 and 11.71 (2s, 1H, NH). ^{13}C -NMR (75 MHz) (DMSO- d_6 /TMS) δ ppm: 18.83, 43.91, 57.40, 115.26, 123.23, 123.80, 124.54, 126.90, 127.46, 128.25, 129.07, 131.15, 132.92, 135.36, 139.80, 145.69, 141.13, 153.46, 160.96, 169.73, 174.90. Anal. Calcd. for $C_{23}H_{20}FN_3O_4$: C, 65.55; H, 4.78; N, 9.97. Found: C, 65.81; H, 4.70; N, 9.96.

N'-(2-chloro-3-methoxybenzylidene)-2-(2-fluoro-[1,1'-biphenyl]-4-yl)propanehydrazide (**3m**): White solid. M.p. 184-184.5°C. Yield 92%. IR ν_{max} (cm^{-1}): 3188 (N-H), 1639 (C=O), 1622 (C=N); 1H -NMR (DMSO- d_6 , 300 MHz) δ (ppm): 1.43 and 1.47 (2d, 3H, $J=7.2$ Hz, CH_3), 3.87-4.79 (m, 4H, CH- CH_3 and $-OCH_3$), 7.16-7.59 (m, 11H, Ar-H), 8.39 and 8.63 (2s, 1H, CH=N), 11.60 and 11.84 (2s, 1H, NH). ^{13}C -NMR (75 MHz) (DMSO- d_6 /TMS) δ ppm: 18.78, 44.12, 56.75, 113.75, 115.83, 118.65, 122.01, 124.55, 126.90, 128.27, 129.06, 133.00, 135.35, 139.88, 155.38, 157.70, 160.96, 169.79, 175.00. Anal. Calcd. for $C_{23}H_{20}ClFN_2O_2$: C, 67.23; H, 4.91; N, 6.82. Found: C, 67.29; H, 50.76; N, 6.96.

N'-(2-Chloro-3-(trifluoromethyl)benzylidene)-2-(2-fluoro-[1,1'-biphenyl]-4-yl)propanehydrazide (**3n**): Off-white solid. M.p. 188-189°C. Yield 79%. IR ν_{max} (cm^{-1}): 3196 (N-H), 1660 (C=O), 1622 (C=N); 1H -NMR (DMSO- d_6 , 300 MHz) δ (ppm): 1.43 and 1.47 (2d, 3H, $J=7.2$ Hz, CH_3), 3.80 and 4.79 (2q, 1H, $J=6.9$ Hz, CH- CH_3), 7.31-8.32 (m, 11H, Ar-H), 8.45 and 8.71 (2s, 1H, CH=N), 11.72 and 11.97 (2s, 1H, NH). ^{13}C -NMR (75 MHz) (DMSO- d_6 /TMS) δ ppm: 18.18, 44.16, 115.63, 122.66, 124.31, 124.58, 125.06, 127.17, 128.38, 129.03, 130.84, 131.23, 135.34, 135.87, 138.49, 143.49, 157.71, 160.97, 169.98, 175.17. Anal. Calcd. for $C_{23}H_{17}ClF_4N_2O$: C, 61.55; H, 3.82; N, 6.24. Found: C, 61.47; H, 3.82; N, 6.25.

N'-[(3,4-Dichlorophenyl)methylidene]-2-(2-fluoro[1,1'-biphenyl]-4-yl)propanehydrazide (**3o**): White solid. M.p. 162-164°C (lit. 166°C³¹). Yield 83%. IR ν_{\max} (cm⁻¹): 3174 (N-H), 1662 (C=O), 1606 (C=N); Anal. Calcd. for C₂₂H₁₇Cl₂FN₂O: C, 63.63; H, 4.13; N, 6.75. Found: C, 63.61; H, 4.02; N, 6.55.

N'-[2,4-Dichlorophenyl)methylidene]-2-(2-fluoro[1,1'-biphenyl]-4-yl)propanehydrazide (**3p**): Off-white solid. M.p. 195-196 °C (lit. 194-195°C³¹). Yield 74%. IR ν_{\max} (cm⁻¹): 3196 (N-H), 1664 (C=O), 1622 (C=N); Anal. Calcd. for C₂₂H₁₇Cl₂FN₂O: C, 63.63; H, 4.13; N, 6.75. Found: C, 63.61; H, 4.02; N, 6.55.

2-(2-Fluoro[1,1'-biphenyl]-4-yl)-*N'*-[(4-methylphenyl)methylidene]propanehydrazide (**3r**): White solid. M.p. 186-187°C (lit. 189-190°C³¹). Yield 95%. IR ν_{\max} (cm⁻¹): 3174 (N-H), 1664 (C=O), 1606 (C=N); Anal. Calcd. for C₂₃H₂₁FN₂O: C, 76.64; H, 5.87; N, 7.77. Found: C, 76.90; H, 5.79; N, 7.72.

2-(2-Fluoro-[1,1'-biphenyl]-4-yl)-*N'*-(4-hydroxy-3-methoxybenzylidene) propane hydrazide (**3s**) : Off-white solid. M.p. 171-173°C (lit. 171-173°C³¹). Yield 81%. IR ν_{\max} (cm⁻¹): 3171 (N-H), 1655 (C=O), 1637 (C=N); Anal. Calcd. for C₂₃H₂₁FN₂O₃: C, 70.40; H, 5.39; N, 7.14. Found: C, 70.63; H, 5.59; N, 7.02.

2.2.2. General procedure for the preparation 2-(2-fluoro-[1,1'-biphenyl]-4-yl)-*N*-(5-methyl-2-(substituted aryl)-4-oxothiazolidine-3-yl)propanamides (**4a-s**)

A mixture of **3a-s** (1 eq.) in dry toluene, thiolactic acid was added (10 eq.) dropwise and refluxed for 10-12 h using Dean-Stark apparatus. After evaporation, the flask content was neutralized by an addition of 5% NaHCO₃ until CO₂ release was completed. The precipitate was washed with water, dried, filtered and recrystallized from ethanol:water mixture (50:50).

N-(2-(4-Cyanophenyl)-5-methyl-4-oxothiazolidine-3-yl)-2-(2-fluoro-[1,1'-biphenyl]-4-yl)propanamide (**4a**): White solid. M.p. 120-121°C. Yield 74%. IR ν_{\max} (cm⁻¹): 3223 (N-H), 2232 (C≡N), 1705 (C=O), 1672 (C=O); ¹H-NMR (DMSO-*d*₆, 300 MHz) δ (ppm): 1.26-1.35 (m, 3H, -CH-CH₃); 1.48-1.54 (m, 3H, thiaz. -CH₃); 3.58-3.68 (m, 1H, thiaz. C₅-H); 4.05-4.24 (m, 1H, -CH-CH₃); 5.84 and 5.89 (2s, 1H, thiaz. C₂-H); 7.00-7.87 (m, 12H, Ar-H); 10.43 and 10.49 (2s, 1H, -CO-NH). ¹³C-NMR (75 MHz) (DMSO-*d*₆/TMS) δ ppm: 18.02, 20.07, 40.75, 59.80, 112.06, 115.41, 123.94, 126.92, 127.10, 128.28, 129.15, 130.87, 132.97, 135.33, 143.03, 143.43, 170.02, 172.17. Anal. Calcd. for C₂₆H₂₂FN₃O₂S.2/3 H₂O: C, 66.22; H, 4.99; N, 8.91; S, 6.80. Found: C, 66.19; H, 4.74; N, 8.79; S, 6.78

2-(2-Fluoro-[1,1'-biphenyl]-4-yl)-*N*-(5-methyl-4-oxo-2-(3-phenoxyphenyl)thiazolidine-3-yl)propanamide (**4b**): White solid. M.p. 122-123°C. Yield 68%. IR ν_{\max} (cm⁻¹): 3314 (N-H), 1705 (C=O), 1669 (C=O); ¹H-NMR (DMSO-*d*₆, 300 MHz) δ (ppm): 1.27-1.36 (m, 3H, -CH-CH₃); 1.45-1.52 (m, 3H, thiaz. -CH₃); 3.63-3.69 (m, 1H, thiaz. C₅-H); 4.02-4.16 (m, 1H, -CH-CH₃); 5.74 (s, 1H, thiaz. C₂-H); 6.90-7.52 (m, 17H, Ar-H); 10.48 and 10.52 (2s, 1H, -CO-NH). ¹³C-NMR (75 MHz) (DMSO-*d*₆/TMS) δ ppm: 18.06, 19.95, 42.54, 60.27, 115.07, 115.38, 118.42, 119.19, 119.31, 123.57, 123.96, 126.88, 128.23, 129.11, 130.46, 130.71, 135.36, 140.05, 143.16, 156.72, 157.10, 157.56, 160.82, 171.99. Anal. Calcd. for C₃₁H₂₇FN₂O₃S.3/4H₂O: C, 68.93; H, 5.32; N, 5.19; S, 5.94. Found: C, 69.04; H, 5.01; N, 5.17; S, 5.47.

2-(2-Fluoro-[1,1'-biphenyl]-4-yl)-*N*-(5-methyl-4-oxo-2-(3-(trifluoromethyl)phenyl)thiazolidine-3-yl)propanamide (**4c**): White solid. M.p. 110-111°C. Yield 68%. IR ν_{\max} (cm⁻¹): 3198 (N-H), 1705 (C=O), 1674 (C=O); ¹H-NMR (DMSO-*d*₆, 300 MHz) δ (ppm): 1.26-1.36 (m, 3H, -CH-CH₃); 1.50-1.55 (m, 3H, thiaz. -CH₃); 3.57-3.68 (m, 1H, thiaz. C₅-H); 4.05-4.24 (m, 1H, -CH-CH₃); 5.90 and 5.93 (2s, 1H, thiaz. C₂-H); 7.00-7.68 (m, 12H, Ar-H); 10.42 and 10.49 (2s, 1H, -CO-NH). ¹³C-NMR (75 MHz) (DMSO-*d*₆/TMS) δ ppm: 18.03, 20.40, 42.86, 50.01, 115.39, 123.90, 124.23, 125.10, 126.13, 126.30, 127.10, 128.23, 129.07, 130.11, 130.85, 135.34, 139.37, 140.44, 143.05, 157.57, 160.88, 172.01. Anal. Calcd. for C₂₆H₂₂F₄N₂O₂S.1/4H₂O: C, 61.59; H, 4.47; N, 5.53; S, 6.32. Found: C, 61.26; H, 4.61; N, 5.37; S, 6.36.

Synthesis and anticancer activity of flurbiprofen derivatives

N-(2-(3-Bromophenyl)-5-methyl-4-oxothiazolidine-3-yl)-2-(2-fluoro-[1,1'-biphenyl]-4-yl)propanamide (**4d**): White solid. M.p. 166-167°C. Yield 58%. IR ν_{\max} (cm⁻¹): 3207 (N-H), 1701 (C=O), 1674 (C=O); ¹H-NMR (DMSO-*d*₆, 300 MHz) δ (ppm): 1.28-1.36 (m, 3H, -CH-CH₃); 1.48-1.54 (m, 3H, thiaz. -CH₃); 3.36-3.70 (m, 1H, thiaz. C₅-H); 4.02-4.19 (m, 1H, -CH-CH₃); 5.73 and 5.75 (2s, 1H, thiaz. C₂-H); 7.02-7.64 (m, 12H, Ar-H); 10.43-10.48 (m, 1H, -CO-NH). ¹³C-NMR (75 MHz) (DMSO-*d*₆/TMS) δ ppm: 18.12, 19.86, 42.55, 59.65, 59.89, 115.36, 122.12, 123.92, 127.11, 128.24, 129.13, 130.78, 131.09, 132.36, 135.37, 140.53, 141.53, 143.08, 157.56, 157.56, 160.82, 171.99. Anal. Calcd. for C₂₅H₂₂BrFN₂O₂S.1/4H₂O: C, 57.98; H, 4.38; N, 5.41; S, 6.19. Found: C, 57.94; H, 4.67; N, 5.54; S, 6.60.

N-(2-(4-Bromophenyl)-5-methyl-4-oxothiazolidine-3-yl)-2-(2-fluoro-[1,1'-biphenyl]-4-yl)propanamide (**4e**): White solid. M.p. 171-172°C. Yield 72%. IR ν_{\max} (cm⁻¹): 3266 (N-H), 1705 (C=O), 1662 (C=O); ¹H-NMR (DMSO-*d*₆, 300 MHz) δ (ppm): 1.27-1.36 (m, 3H, -CH-CH₃); 1.50-1.54 (m, 3H, thiaz. -CH₃); 3.60-3.66 (m, 1H, thiaz. C₅-H); 4.04-4.17 (m, 1H, -CH-CH₃); 5.72 and 5.78 (2s, 1H, thiaz. C₂-H); 7.00-7.61 (m, 12H, Ar-H); 10.39 and 10.42 (2s, 1H, -CO-NH). ¹³C-NMR (75 MHz) (DMSO-*d*₆/TMS) δ ppm: 17.97, 19.82, 42.56, 44.71, 59.90, 115.11, 122.70, 123.95, 125.78, 128.87, 128.67, 129.15, 130.86, 131.98, 135.32, 137.07, 137.81, 143.15, 160.79, 172.10. Anal. Calcd. for C₂₅H₂₂BrFN₂O₂S: C, 58.48; H, 4.32; N, 5.46; S, 6.25. Found: C, 58.69; H, 4.60; N, 5.35; S, 6.34.

N-(2-(Benzo[*d*][1,3]dioxol-4-yl)-5-methyl-4-oxothiazolidine-3-yl)-2-(2-fluoro-[1,1'-biphenyl]-4-yl)propanamide (**4f**): Dark yellow solid. M.p. 177-178°C. Yield 50%. IR ν_{\max} (cm⁻¹): 3188 (N-H), 1705 (C=O), 1670 (C=O); ¹H-NMR (DMSO-*d*₆, 300 MHz) δ (ppm): 1.28-1.37 (m, 3H, -CH-CH₃); 1.46-1.53 (m, 3H, thiaz. -CH₃); 3.64-3.73 (m, 1H, thiaz. C₅-H); 4.01-4.16 (m, 1H, -CH-CH₃); 5.78-6.04 (m, 3H, thiaz. C₂-H and O-CH₂-O); 6.72-7.65 (m, 11H, Ar-H); 10.47 and 10.50 (2s, 1H, -CO-NH). ¹³C-NMR (75 MHz) (DMSO-*d*₆/TMS) δ ppm: 17.89, 19.74, 42.33, 55.01, 55.36, 101.76, 109.21, 115.26, 119.11, 120.64, 121.98, 122.86, 127.00, 129.10, 129.14, 130.83, 135.35, 143.13, 145.98, 147.65, 165.68, 171.50, 172.05. Anal. Calcd. for C₂₆H₂₃FN₂O₄S.1/4H₂O: C, 64.65; H, 4.90; N, 5.80; S, 6.64. Found: C, 64.32; H, 4.83; N, 5.82; S, 6.31.

N-(2-(2,6-Dichlorophenyl)-5-methyl-4-oxothiazolidine-3-yl)-2-(2-fluoro-[1,1'-biphenyl]-4-yl)propanamide (**4g**): White solid. M.p. 339-340°C. Yield 80%. IR ν_{\max} (cm⁻¹): 3219 (N-H), 1711 (C=O), 1676 (C=O); ¹H-NMR (DMSO-*d*₆, 300 MHz) δ (ppm): 1.24-1.36 (m, 3H, -CH-CH₃); 1.50-1.55 (m, 3H, thiaz. -CH₃); 3.62-3.75 (m, 1H, thiaz. C₅-H); 4.11-4.20 (m, 1H, -CH-CH₃); 6.40 (s, 1H, thiaz. C₂-H); 7.01-7.57 (m, 11H, Ar-H); 10.25 (bs, 1H, -CO-NH). Anal. Calcd. for C₂₅H₂₁Cl₂FN₂O₂S: C, 59.65; H, 4.20; N, 5.56; S, 6.37. Found: C, 59.90; H, 4.33; N, 5.42; S, 6.31.

N-(2-(3,5-Bis(trifluoromethyl)phenyl)-5-methyl-4-oxothiazolidine-3-yl)-2-(2-fluoro-[1,1'-biphenyl]-4-yl)propanamide (**4h**): Light yellow solid. M.p. 220-222°C. Yield 84%. IR ν_{\max} (cm⁻¹): 3262 (N-H), 1732 (C=O), 1672 (C=O); ¹H-NMR (DMSO-*d*₆, 300 MHz) δ (ppm): 1.25-1.56 (m, 6H, -CH-CH₃ and thiaz. -CH₃); 3.57-3.68 (m, 1H, thiaz. C₅-H); 4.10-4.35 (m, 1H, -CH-CH₃); 6.04 and 6.08 (2s, 1H, thiaz. C₂-H); 6.94-8.18 (m, 11H, Ar-H); 10.43 and 10.56 (2s, 1H, -CO-NH). ¹³C-NMR (75 MHz) (DMSO-*d*₆/TMS) δ ppm: 18.13, 20.05, 40.72, 42.68, 59.17, 114.94, 115.28, 121.73, 123.81, 125.32, 127.15, 128.22, 129.02, 131.19, 141.68, 143.07, 157.47, 167.38, 172.03. Anal. Calcd. for C₂₇H₂₁F₇N₂O₂S.3/2H₂O: C, 56.59; H, 3.75; N, 4.89; S, 5.59. Found: C, 56.07; H, 3.75; N, 4.67; S, 5.79.

2-(2-Fluoro-[1,1'-biphenyl]-4-yl)-*N*-(5-methyl-4-oxo-2-(2-(trifluoromethoxy)phenyl)thiazolidine-3-yl)propanamide (**4i**): Off-white solid. M.p. 91-93°C. Yield 81%. IR ν_{\max} (cm⁻¹): 3227 (N-H), 1717 (C=O), 1668 (C=O); ¹H-NMR (DMSO-*d*₆, 300 MHz) δ (ppm): 1.25-1.36 (m, 3H, -CH-CH₃); 1.49-1.54 (m, 3H, thiaz. -CH₃); 3.39-3.68 (m, 1H, thiaz. C₅-H); 4.10-4.21 (m, 1H, -CH-CH₃); 6.08 (m, 1H, thiaz. C₂-H); 7.07-7.71 (m, 12H, Ar-H); 10.52 and 10.56 (2s, 1H, -CO-NH). ¹³C-NMR (75 MHz) (DMSO-*d*₆/TMS) δ ppm: 18.45, 20.15, 42.64, 58.26, 63.60, 113.34, 120.92, 123.89, 125.48, 126.27, 127.15, 127.61, 128.09, 128.22, 129.09, 135.36, 145.29, 152.06, 163.76, 169.21, 172.25. Anal. Calcd. for C₂₆H₂₂F₄N₂O₃S.H₂O: C, 58.20; H, 4.51; N, 5.22; S, 5.98. Found: C, 58.39; H, 4.33; N, 5.25; S, 5.95.

N-(2-(4-bromothiophen-2-yl)-5-methyl-4-oxothiazolidine-3-yl)-2-(2-fluoro-[1,1'-biphenyl]-4-yl)propanamide (**4j**): Pale yellow solid. M.p. 119-121°C. Yield 56%. IR ν_{\max} (cm⁻¹): 3181 (N-H), 1715 (C=O), 1695 (C=O); ¹H-NMR (DMSO-*d*₆, 300 MHz) δ (ppm): 1.35-1.39 (m, 3H, -CH-CH₃); 1.47-1.54 (m, 3H, thiaz. -CH₃); 3.69-3.76 (m, 1H, thiaz. C₅-H); 4.02-4.16 (m, 1H, -CH-CH₃); 5.98 and 6.44 (2s, 1H, thiaz. C₂-H); 7.15-7.780 (m, 10H, Ar-H); 10.53 (s, 1H, -CO-NH). ¹³C-NMR (75 MHz) (DMSO-*d*₆/TMS) δ ppm: 18.32, 20.25, 42.64, 55.56, 55.95, 108.39, 115.52, 126.33, 127.29, 126.43, 128.24, 129.19, 131.61, 135.39, 143.99, 157.69, 160.95, 171.42, 172.09. Anal. Calcd. for C₂₃H₂₀BrFN₂O₂S₂.1/4H₂O: C, 52.72; H, 3.94; N, 5.35; S, 12.24 Found: C, 52.58; H, 3.94; N, 5.32; S, 12.56.

N-(2-(5-Bromo-2-methoxyphenyl)-5-methyl-4-oxothiazolidine-3-yl)-2-(2-fluoro-[1,1'-biphenyl]-4-yl)propanamide (**4k**): Yellow solid. M.p. 111-112°C. Yield 68%. IR ν_{\max} (cm⁻¹): 3254 (N-H), 1714 (C=O), 1668 (C=O); ¹H-NMR (DMSO-*d*₆, 300 MHz) δ (ppm): 1.30-1.50 (m, 6H, -CH-CH₃ and thiaz. -CH₃); 3.64-3.66 (m, 3H, -OCH₃); 3.80 (m, 1H, thiaz. C₅-H); 4.00-4.15 (m, 1H, -CH-CH₃); 5.91-6.04 (m, 1H, thiaz. C₂-H); 6.90-7.56 (m, 11H, Ar-H); 10.58 (s, 1H, -CO-NH). ¹³C-NMR (75 MHz) (DMSO-*d*₆/TMS) δ ppm: 18.19, 20.21, 42.53, 56.33, 56.54, 112.64, 114.05, 115.23, 123.99, 124.83, 125.74, 128.24, 129.09, 130.89, 132.92, 135.36, 143.11, 156.78, 172.13, 172.60. Anal. Calcd. for C₂₆H₂₄BrFN₂O₃S₂.H₂O: C, 55.62; H, 4.67; N, 4.99; S, 5.71 Found: C, 55.43; H, 4.63; N, 5.16; S, 5.70.

2-(2-Fluoro-[1,1'-biphenyl]-4-yl)-*N*-(2-(4-methoxy-3-nitrophenyl)-5-methyl-4-oxothiazolidine-3-yl)propanamide (**4l**): Yellow solid. M.p. 108-109°C. Yield 54%. IR ν_{\max} (cm⁻¹): 3256 (N-H), 1717 (C=O), 1688 (C=O); ¹H-NMR (DMSO-*d*₆, 300 MHz) δ (ppm): 1.27-1.35 (m, 3H, -CH-CH₃); 1.49-1.54 (m, 3H, thiaz. -CH₃); 3.54-3.66 (m, 3H, -OCH₃); 3.54-3.66 (m, 1H, thiaz. C₅-H); 4.04-4.24 (m, 1H, -CH-CH₃); 5.84 (s, 1H, thiaz. C₂-H); 7.01-7.98 (m, 11H, Ar-H); 10.38 and 10.45 (2s, 1H, -CO-NH). ¹³C-NMR (75 MHz) (DMSO-*d*₆/TMS) δ ppm: 18.19, 20.21, 42.53, 56.33, 56.54, 112.64, 114.05, 115.23, 123.99, 124.83, 125.74, 128.24, 129.09, 130.89, 132.92, 135.36, 143.11, 156.78, 172.13, 172.60. Anal. Calcd. for C₂₆H₂₄BrFN₂O₃S₂.H₂O: C, 55.62; H, 4.67; N, 4.99; S, 5.71 Found: C, 55.43; H, 4.63; N, 5.16; S, 5.70.

N-(2-(2-Chloro-3-methoxyphenyl)-5-methyl-4-oxothiazolidine-3-yl)-2-(2-fluoro-[1,1'-biphenyl]-4-yl)propanamide (**4m**): Off-white solid. M.p. 133-135°C. Yield 85%. IR ν_{\max} (cm⁻¹): 3205 (N-H), 1705 (C=O), 1663 (C=O); ¹H-NMR (DMSO-*d*₆, 300 MHz) δ (ppm): 1.28-1.37 (m, 3H, -CH-CH₃); 1.48-1.54 (m, 3H, thiaz. -CH₃); 3.59-3.69 (m, 1H, thiaz. C₅-H); 4.06-4.25 (m, 1H, -CH-CH₃); 5.77-5.82 (m, 1H, thiaz. C₂-H); 7.02-7.573 (m, 11H, Ar-H); 10.39 (s, 1H, -CO-NH). ¹³C-NMR (75 MHz) (DMSO-*d*₆/TMS) δ ppm: 18.06, 19.91, 42.65, 59.07, 59.29, 115.05, 123.90, 126.96, 128.24, 128.76, 129.14, 126.80, 131.14, 130.17, 138.99, 140.02, 143.08, 157.55, 160.79, 171.97, 172.06. Anal. Calcd. for C₂₅H₂₁Cl₂FN₂O₂S.1/2H₂O: C, 58.60; H, 4.33; N, 5.47; S, 6.26 Found: C, 58.25; H, 4.49; N, 5.43; S, 6.67.

N-(2-(2-Chloro-3-(trifluoromethyl)phenyl)-5-methyl-4-oxothiazolidine-3-yl)-2-(2-fluoro-[1,1'-biphenyl]-4-yl)propanamide (**4n**): White solid. M.p. 161-163°C. Yield 52%. IR ν_{\max} (cm⁻¹): 3252 (N-H), 1716 (C=O), 1668 (C=O); ¹H-NMR (DMSO-*d*₆, 300 MHz) δ (ppm): 1.31-1.54 (m, 6H, -CH-CH₃ and thiaz. -CH₃); 3.66-3.70 (m, 1H, thiaz. C₅-H); 4.11-4.20 (m, 1H, -CH-CH₃); 6.18- 6.26 (m, 1H, thiaz. C₂-H); 6.98-7.68 (m, 11H, Ar-H); 10.57 and 10.66 (2s, 1H, -CO-NH). ¹³C-NMR (75 MHz) (DMSO-*d*₆/TMS) δ ppm: 18.08, 18.87, 42.67, 51.43, 114.94, 123.72, 124.41, 128.21, 128.79, 129.00, 129.79, 130.80, 131.02, 133.04, 135.27, 142.91, 143.02, 172.18, 172.45, 172.58. Anal. Calcd. for C₂₆H₂₁ClF₄N₂O₂S: C, 58.16; H, 3.94; N, 5.22; S, 5.97 Found: C, 57.88; H, 3.98; N, 5.26; S, 6.51.

N-(2-(3,4-Dichlorophenyl)-5-methyl-4-oxothiazolidine-3-yl)-2-(2-fluoro-[1,1'-biphenyl]-4-yl)propanamide (**4o**): White solid. M.p. 133-135°C. Yield 52%. IR ν_{\max} (cm⁻¹): 3246 (N-H), 1705 (C=O), 1662 (C=O); ¹H-NMR (DMSO-*d*₆, 300 MHz) δ (ppm): 1.28-1.37 (m, 3H, -CH-CH₃); 1.48-1.54 (m, 3H, thiaz. -CH₃); 3.59-3.69 (m, 1H, thiaz. C₅-H); 4.06-4.25 (m, 1H, -CH-CH₃); 5.77-5.82 (m, 1H, thiaz. C₂-H); 7.02-7.73 (m, 11H, Ar-H); 10.39 and 10.46 (2s, 1H, -CO-NH). ¹³C-NMR (75 MHz) (DMSO-*d*₆/TMS) δ ppm: 18.06, 19.91, 42.65, 59.07, 59.29, 115.05, 123.90, 126.96, 128.24, 128.76,

Synthesis and anticancer activity of flurbiprofen derivatives

129.14, 126.80, 131.14, 130.17, 138.99, 140.02, 143.08, 157.55, 160.79, 171.97, 172.06. Anal. Calcd. for $C_{25}H_{21}Cl_2FN_2O_2S \cdot 1/2H_2O$: C, 58.60; H, 4.33; N, 5.47; S, 6.26 Found: C, 58.25; H, 4.49; N, 5.43; S, 6.77.

N-(2-(2,4-Dichlorophenyl)-5-methyl-4-oxothiazolidine-3-yl)-2-(2-fluoro-[1,1'-biphenyl]-4-yl)propanamide (**4p**): White solid. M.p. 112-114°C. Yield 80%. IR ν_{max} (cm^{-1}): 3290 (N-H), 1717 (C=O), 1674 (C=O); 1H -NMR (DMSO- d_6 , 300 MHz) δ (ppm): 1.29-1.37 (m, 3H, -CH-CH₃); 1.48-1.53 (m, 3H, thiaz. -CH₃); 3.60-3.69 (m, 1H, thiaz. C₅-H); 4.08-4.18 (m, 1H, -CH-CH₃); 6.01-6.12 (m, 1H, thiaz. C₂-H); 7.00-7.66 (m, 11H, Ar-H); 10.52 and 10.59 (2s, 1H, -CO-NH). ^{13}C -NMR (75 MHz) (DMSO- d_6 /TMS) δ ppm: 17.93, 20.07, 42.63, 56.62, 114.99, 123.85, 127.13, 128.24, 128.53, 129.14, 130.85, 133.87, 133.93, 134.15, 134.53, 135.36, 143.04, 171.97, 172.10, 172.34. Anal. Calcd. for $C_{25}H_{21}Cl_2FN_2O_2S \cdot 3/2H_2O$: C, 56.61; H, 4.56; N, 5.13 Found: C, 56.79; H, 4.55; N, 5.12.

2-(2-Fluoro-[1,1'-biphenyl]-4-yl)-*N*-(5-methyl-4-oxothiazolidine-2-(*p*-tolyl)-3-yl)propanamide (**4r**): White solid. M.p. 143-145°C. Yield 72%. IR ν_{max} (cm^{-1}): 3234 (N-H), 1703 (C=O), 1674 (C=O); 1H -NMR (DMSO- d_6 , 300 MHz) δ (ppm): 1.26-1.35 (m, 3H, -CH-CH₃); 1.49-1.54 (m, 3H, thiaz. -CH₃); 2.22-2.31 (s, 3H, tolyl -CH₃); 3.57-3.68 (m, 1H, thiaz. C₅-H); 4.01-4.15 (m, 1H, -CH-CH₃); 5.71 and 5.77 (2s, 1H, thiaz. C₂-H); 7.16-7.55 (m, 12H, Ar-H); 10.36 (s, 1H, -CO-NH). ^{13}C -NMR (75 MHz) (DMSO- d_6 /TMS) δ ppm: 17.97, 18.91, 21.19, 42.47, 60.27, 60.87, 115.42, 123.98, 127.01, 128.47, 129.11, 129.43, 130.83, 134.35, 135.38, 139.12, 143.16, 171.93, 172.09, 172.21. Anal. Calcd. for $C_{26}H_{25}FN_2O_2S \cdot 1/2H_2O$: C, 68.25; H, 5.73; N, 6.12; S, 7.01 Found: C, 68.81; H, 5.50; N, 6.32; S, 6.77.

2-(2-Fluoro-[1,1'-biphenyl]-4-yl)-*N*-(2-(4-hydroxy-3-methoxyphenyl)-5-methyl-4-oxothiazolidine-3-yl)propanamide (**4s**): Off-white solid. M.p. 70-72°C. Yield 80%. IR ν_{max} (cm^{-1}): 3240 (N-H), 1709 (C=O), 1666 (C=O); 1H -NMR (DMSO- d_6 , 300 MHz) δ (ppm): 1.27-1.35 (m, 3H, -CH-CH₃); 1.48-1.54 (m, 3H, thiaz. -CH₃); 3.66 (s, 3H, -OCH₃); 3.76 (s, 1H, thiaz. C₅-H); 3.99-4.11 (m, 1H, -CH-CH₃); 5.64- 5.74 (m, 1H, thiaz. C₂-H); 6.64-7.55 (m, 11H, Ar-H); 9.31 (s, 1H, -OH); 10.34 (s, 1H, -CO-NH). ^{13}C -NMR (75 MHz) (DMSO- d_6 /TMS) δ ppm: 18.20, 20.68, 42.44, 55.80, 55.95, 60.97, 112.14, 115.61, 121.54, 124.04, 126.89, 127.61, 128.24, 129.10, 130.85, 135.38, 143.13, 147.97, 148.10, 157.57, 160.82, 172.01. Anal. Calcd. for $C_{26}H_{25}FN_2O_4S \cdot H_2O$: C, 62.64; H, 5.46; N, 5.62; S, 6.03 Found: C, 62.42; H, 5.02; N, 5.75; S, 5.93.

2.3. Biological Assay

2.3.1. Cell Culture

Human breast cancer cell line MCF-7 (ATCC[®], HTB22[™]), human colon cancer cell line HT-29 (ATCC[®], HTB-38[™]), human lung cancer cell line A549 (ATCC[®], CCL-185[™]), human cervical carcinoma cell line HeLa (ATCC[®], CCL2[™]), and mouse fibroblast embryonic cell line NIH3T3 (ATCC[®], CRL-1658) were maintained in DMEM (Dulbecco's Modified Eagle Medium) supplemented with 10% FBS (Fetal bovine serum), 1% L-Glutamine and penicillin/streptomycin (Gibco) at 37°C in a humidified incubator with 5% CO₂.

2.3.2. Cell Viability Assay


Cell viability was determined by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay following the procedure of Kulabaş et al.³² Viability was calculated as follows:

$$\text{Cell Viability (\%)} = (A_{\text{treatment}} - A_{\text{blank}}) / (A_{\text{control}} - A_{\text{blank}}) \times 100\% \text{ (where, A = absorbance).}$$

3. Results and Discussion

3.1. Chemistry

The general methods for synthesis of target hydrazone and 4-thiazolidinone derivatives are depicted in Scheme 1. The starting methyl (\pm) (R,S)-2-(2-fluorobiphenyl-4-yl)propanoate (**1**) synthesized using known methods from (\pm) (R,S)-flurbiprofen²⁹ easily reacted with hydrazine hydrate in ethanol yielding (\pm) (R,S)-2-(2-fluorobiphenyl-4-yl)propanehydrazide (**2**).²⁸⁻³⁰ Based on the condensation reaction of **2** and substituted aldehydes in the presence of acetic acid, (\pm) (R,S)-2-(2-fluorobiphenyl-4-yl)-N'-(substituted methylene)propanehydrazides (**3a-s**) were obtained. Finally, 2-(2-fluoro-[1,1'-biphenyl]-4-yl)-N-(5-methyl-2-(substituted aryl)-4-oxothiazolidin-3-yl)propanamide derivatives (**4a-s**) were synthesized by the treatment of **3a-s** with a large excess of thiolactic acid ((R,S)-2-mercapto propionic acid) in the presence of toluene.²⁸ The compounds (**3d**, **3o**, **3p**, **3r**, **3s**) have been previously synthesized and reported in the literature.^{30, 31} while the other compounds are the original compounds reported in this study. In this study, the structures characterization of original compounds were studied by FT-IR, NMR and elemental microanalysis and their antiproliferative activities were evaluated using MTT assay.



Compound	-Ar	Compound	-Ar
a	4-cyanophenyl	j	4-bromothiophen-2-yl
b	3-phenoxyphenyl	k	5-bromo-2-methoxyphenyl
c	3-(trifluoromethyl)phenyl	l	4-methoxy-3-nitrophenyl
d	3-bromophenyl	m	2-chloro-3-methoxyphenyl
e	4-bromophenyl	n	2-chloro-3-(trifluoromethyl)phenyl
f	benzo[d][1,3]dioxol-4-yl	o	3,4-dichlorophenyl
g	2,6-dichlorophenyl	p	2,4-dichlorophenyl
h	3,5-bis(trifluoromethyl)phenyl	r	p-tolyl
i	2-(trifluoromethoxy)phenyl	s	4-hydroxy-3-methylphenyl

Scheme 1. Synthesis of the title compounds **3a-s** and **4a-s**

Synthesis and anticancer activity of flurbiprofen derivatives

The structures of the target compounds **3a-s** and **4a-s** were elucidated by FT-IR and NMR spectral studies and elemental analysis. The FT-IR spectra of all the synthesized compounds displayed characteristic absorption band for N-H, C=O and/or C=N groups.

According to literature, the hydrazones may exist as *Z/E* geometrical isomers about imine bonds and *cis/trans* amide conformers.^{33,34} ¹H-NMR spectra of compounds **3a-s** display two sets of singlets each belonging to the -CH-CH₃, -NH and =CH protons in DMSO-*d*₆, indicating the presence of *cis/trans* conformers (see Figure S2).

The synthesis of thiazolidin-4-one moiety was evident by the presence of frequency ranged from 1699-1732 cm⁻¹ characteristic C=O group at the 4th position. The proton resonance at 5.71-6.44 ppm in the spectra were attributed to 4-thiazolidinone C2-H position.^{35,36} Generally, two sets of singlet or multiplet signals were determined for most of the protons of the thiazolidinones, and this is because of the magnetically inequivalent protons on chiral center.³⁶

3.2. Biological Assay

3.2.1. Antiproliferative Activity

The antiproliferative activity of all the synthesized hydrazone and thiazolidinone compounds were evaluated *in vitro* against four human cancer cell lines (the colorectal adenocarcinoma cell line HT-29, the cervical carcinoma HeLa cells, the lung cancer cell line A549, as well as the breast cancer cell line MCF-7) at 10 μM concentration. In addition, cytotoxicity results against mouse fibroblast cell line NIH3T3 (ATCC[®], CRL-1658TM) at 10 μM dose of compounds **3a-s** and **4a-s** were given in Table 1 and these compounds appeared to be safe towards NIH3T3 fibroblasts.

Table 1. Cytotoxicity and antiproliferative activity of compounds **3a-s** and **4a-s** in selected cancer cell lines

Comp.	% proliferation (at 10 μM)					Comp.	% proliferation (at 10 μM)				
	HT-29	HeLa	A549	MCF-7	NIH3T3		HT-29	HeLa	A549	MCF-7	NIH3T3
3a	100.49	106.06	95.58	93.28	128.83	4a	86.75	102.78	96.77	92.63	110.46
3b	99.34	98.56	104.50	89.99	122.45	4b	88.15	95.96	93.11	79.31	103.02
3c	95.31	95.38	79.36	92.37	94.56	4c	84.12	87.98	82.77	82.51	80.84
3d	91.36	105.48	97.79	85.49	103.32	4d	88.15	97.98	91.29	99.24	89.33
3e	94.90	104.71	99.22	84.66	117.86	4e	69.96	109.52	94.97	85.42	95.72
3f	93.09	101.83	94.45	86.92	111.82	4f	74.16	101.06	82.14	84.76	84.28
3g	90.04	99.13	95.81	88.13	109.78	4g	77.53	102.60	86.66	87.13	92.63
3h	72.59	100.38	65.27	69.41	90.56	4h	44.03	85.67	78.09	72.56	78.18
3i	90.88	124.28	125.13	88.87	118.03	4i	87.00	87.79	84.97	83.25	82.60
3j	88.67	116.86	102.47	66.02	97.62	4j	98.77	99.81	95.31	86.25	87.51
3k	93.56	97.64	114.65	90.13	109.35	4k	85.10	100.87	133.44	96.08	78.11
3l	88.37	101.81	105.63	96.44	115.82	4l	87.33	89.71	93.78	88.46	89.26
3m	82.46	105.42	108.88	92.88	119.64	4m	92.35	85.38	98.02	84.73	82.46
3n	88.53	103.20	105.13	87.97	120.92	4n	78.68	74.90	80.56	76.89	79.93
3o	87.93	88.17	75.61	85.08	71.68	4o	94.57	99.13	84.41	82.30	75.02
3p	82.18	80.68	94.55	76.48	114.2	4p	87.41	86.83	87.34	90.21	82.25
3r	92.60	116.40	94.14	92.29	107.06	4r	90.62	96.15	114.68	110.85	77.96
3s	89.71	93.94	88.24	66.51	115.39	4s	97.20	87.50	116.92	99.28	90.18

According to data, the most active compound was identified as compound *N*-(2-(3,5-bis(trifluoromethyl)phenyl)-5-methyl-4-oxothiazolidin-3-yl)-2-(2-fluoro-[1,1'-biphenyl]-4-yl)propanamide (**4h**) by 55.97% inhibition in HT-29 cell line. This compound was observed non-toxic to NIH3T3 mouse fibroblast cells with high survival rate (78.18%). Other remarkable inhibitions were

observed with compounds *N*-(3,5-bis(trifluoromethyl)benzylidene)-2-(2-fluoro-[1,1'-biphenyl]-4-yl)propanehydrazide (**3h**) (34.73% inhibition vs. A549), *N*-[(4-bromothiophen-2-yl)methylidene]-2-(2-fluoro[1,1'-biphenyl]-4-yl)propanehydrazide (**3j**) (33.98% inhibition vs. MCF-7) and 2-(2-fluoro-[1,1'-biphenyl]-4-yl)-*N*-(4-hydroxy-3-methoxybenzylidene)propanehydrazide (**3s**) (33.49% inhibition vs. MCF-7) at 10 μ M concentration.

4. Conclusion

In this present study, we have described the synthesis and identification of flurbiprofen hydrazones and 4-thiazolidinones which were tested for antiproliferative activity against HT-29, HeLa, A549 and MCF-7 cancer cell lines. NIH/3T3 fibroblast proliferation was also tested and cell proliferation was found to be between 128.83% and 71.68%, which means that all the compounds were nontoxic. Among these derivatives, non-toxic compound **4h** caused significant decrease (55.97%) in HT-29 colorectal adenocarcinoma cell proliferation at 10 μ M concentration. Regarding these flurbiprofen analogs, we can conclude that the replacement of 4-thiazolidinone ring with 5-methyl-4-thiazolidinone ring did not considerably affect the activity.

Acknowledgements

This work was supported by the Research Fund of Marmara University, Project Number: SAG-A-130219-0045.

Conflict of interest statement

The authors declared no conflict of interest.

ORCID

Pelin Süzgün: [0000-0001-6661-6025](https://orcid.org/0000-0001-6661-6025)

Sevil Şenkardeş: [0000-0002-0523-459X](https://orcid.org/0000-0002-0523-459X)

Merve Gürboğa: [0000-0003-4614-7094](https://orcid.org/0000-0003-4614-7094)

Özlem Bingöl Özakpınar: [0000-0003-0287-5639](https://orcid.org/0000-0003-0287-5639)

Ş.Güniz Küçükgül: [0000-0001-9405-8905](https://orcid.org/0000-0001-9405-8905)

References

- [1] Bora, V.R.; Patel, B.M. The deadly duo of COVID-19 and cancer!, *Front. Mol. Biosci.* **2021**, *8*, 643004.
- [2] Şenkardeş, S.; Küçükgül, Ş.G. Recent progress on synthesis and anticancer activity of 4-thiazolidinone. *Mini Rev. Org. Chem.* **2016**, *13*, 377–388.
- [3] Şenkardeş, S.; B, Özakpınar Ö.; Özsvacı, D.; Şener, A.; Çevik, Ö.; Küçükgül, Ş.G. Synthesis of diflunisal thiazolidinones as anticancer agents. *Anticancer Agents Med. Chem.* **2016**, *16*, 1266–1274.
- [4] Türe, A.; Ergül, M.; Ergül, M.; Altun, A.; Küçükgül, İ. Design, synthesis, and anticancer activity of novel 4-thiazolidinone-phenylaminopyrimidine hybrids. *Mol. Divers.* **2021**, *25*, 1025–1050.
- [5] Zhang, H.; Zhang, J.; Qu, W.; Xie, S.; Huang, L.; Chen, D.; Tao, Y.; Liu, Z.; Pan, Y.; Yuan, Z. Design, synthesis, and biological evaluation of novel thiazolidinone-containing quinoxaline-1,4-di-*N*-oxides as antimycobacterial and antifungal agents. *Front. Chem.* **2020**, *8*, 598.
- [6] Kaushik-Basu, N.; Bopda-Waffo, A.; Talele, T.T.; Basu, A.; Chen, Y.; Küçükgül, Ş.G. 4-Thiazolidinones: A novel class of hepatitis C virus NS5B polymerase inhibitors. *Front. Biosci.* **2008**, *13*, 3857–3868.
- [7] Küçükgül, Ş.G.; Kocatepe, A.; De Clercq, E.; Şahin, F.; Güllüce, M. Synthesis and biological activity of 4-thiazolidinones, thiosemicarbazides derived from diflunisal hydrazide. *Eur. J. Med. Chem.* **2006**, *41*, 353–359.

Synthesis and anticancer activity of flurbiprofen derivatives

- [8] Dincel, E.D.; Ulusoy-Güzeldemirci, N.; Şatana, D.; Küçükbasmacı, Ö. Design, synthesis, characterization and antimicrobial evaluation of some novel hydrazinecarbothioamide, 4-thiazolidinone and 1,2,4-triazole-3-thione derivatives. *J. Heterocycl. Chem.* **2021**, *58*, 195–205.
- [9] Küçükgülzel, Ş.G.; Oruç, E.E.; Rollas, S.; Şahin, F.; Özbek, A. Synthesis, characterisation and biological activity of novel 4-thiazolidinones, 1,3,4-oxadiazoles and some related compounds. *Eur. J. Med. Chem.* **2002**, *37*, 197–206.
- [10] Anekal, D.P.; Biradar, J.S. Synthesis and biological evaluation of novel Indolyl 4-thiazolidinones bearing thiadiazine nucleus. *Arab. J. Chem.* **2017**, *10*, S2098–S2105.
- [11] Maccari, R.; Del Corso, A.; Paoli, P.; Adornato, I.; Lori, G.; Balestri, F.; Cappiello, M.; Nab, A.; Wolber, G.; Ottana, R. An investigation on 4-thiazolidinone derivatives as dual inhibitors of aldose reductase and protein tyrosine phosphatase 1B, in the search for potential agents for the treatment of type 2 diabetes mellitus and its complications. *Bioorg. Med. Chem. Lett.* **2018**, *28*, 3712–3720.
- [12] Keogh, A.; Şenkardeş, S.; Idle, J.R.; Küçükgülzel, Ş.G.; Beyoğlu, D. A novel anti-hepatitis C virus and antiproliferative agent alters metabolic networks in HepG2 and Hep3B cells. *Metabolites* **2017**, *7*, 1–16.
- [13] Rollas, S.; Küçükgülzel, Ş.G. Biological activities of hydrazone derivatives. *Molecules* **2007**, *12*, 1910–1939.
- [14] Çıkla-Süzgün, P.; Küçükgülzel, Ş.G. Recent advances in apoptosis: the role of hydrazones. *Mini Rev. Med. Chem.* **2019**, *19*, 1427–1442.
- [15] Tatar, E.; Şenkardeş, S.; Sellitepe, H.E.; Küçükgülzel, Ş.G.; Karaoğlu, Ş.A.; Bozdeveci, A.; Clerco, E.D.; Pannecouque, C.; Hadda, T.B.; Küçükgülzel, İ. Synthesis, and prediction of molecular properties and antimicrobial activity of some acylhydrazones derived from *N*-(arylsulfonyl)methionine. *Turkish J. Chem.* **2016**, *40*, 510–534.
- [16] Şenkardeş, S.; Erdoğan, Ö.; Çevik, Ö.; Küçükgülzel, Ş.G. Synthesis and biological evaluation of novel aryloxyacetic acid hydrazide derivatives as anticancer agents. *Synth. Commun.* **2021**, *51*, 2634–2643.
- [17] Yankin, A.N.; Nosova, N.V.; Novikova, V.V.; Gein, V.L. Synthesis and antimicrobial activity of novel hydrazone and 1,2,4-triazole-3-thione derivatives. *Russ. J. Gen. Chem.* **2022**, *92*, 166–173.
- [18] Şenkardeş, S.; Kulabaş, N.; Küçükgülzel, Ş.G. Synthesis, molecular docking studies and ADME prediction of some new albendazole derivatives as α -glucosidase inhibitors. *Acta Chim. Slov.* **2022**, *69*, 526–535.
- [19] Çıkla, P.; Özsavcı, D.; Bingöl-Özakpınar, Ö.; Şener, A.; Çevik, Ö.; Özbaş-Turan, S.; Akbuğa J.; Şahin, F.; Küçükgülzel, Ş.G. Synthesis, cytotoxicity, and pro-apoptosis activity of etodolac hydrazide derivatives as anticancer agents. *Arch. Pharm. (Weinheim)*. **2013**, *346*, 367–379.
- [20] Küçükgülzel, Ş.G.; Koç, D.; Çıkla-Süzgün, P.; Özsavcı, D.; Bingöl-Özakpınar, Ö.; Mega-Tiber, P.; Orun, O.; Erzincan, P.; Sağ-erdem, S.; Şahin, F. Synthesis of tolmetin hydrazide-hydrazones and discovery of a potent apoptosis inducer in colon cancer cells. *Arch. Pharm. (Weinheim)*. **2015**, *348*, 730–742.
- [21] Han, M.İ.; Atalay, P.; Tunç, C.Ü.; Ünal, G.; Dayan, S.; Aydın, Ö.; Küçükgülzel, Ş.G. Design and synthesis of novel (S)-naproxen hydrazide-hydrazones as potent VEGFR-2 inhibitors and their evaluation in vitro/in vivo breast cancer models. *Bioorg. Med. Chem.* **2021**, *37*, 116097.
- [22] Han, M.İ.; Yeşil Baysal, Ö.D.; Başaran, G.Ş.; Sezer, G.; Telci, D.; Küçükgülzel, Ş.G. Design, synthesis and anticancer activity studies of novel 4-butylaminophenyl hydrazide-hydrazones as apoptotic inducers. *Tetrahedron* **2022**, *115*, 132797.
- [23] Koç, H.C.; Atlıhan, İ.; Mega-Tiber, P.; Orun, O.; Küçükgülzel, G. Synthesis of some novel hydrazide-hydrazones derived from etodolac as potential anti-prostate cancer agents. *J. Res. Pharm.* **2022**, *26*, 1–12.
- [24] Atlıhan, İ.; Koçyiğit Sevinç, S.; Orun, O.; Yılmaz, Ö.; Küçükgülzel, Ş. G.; Mega Tiber, P. Effect of flurbiprofen derivative (SGK597) on cell proliferation and apoptosis of breast cancer cell lines. *Istanbul J. Pharm.* **2022**, *52*, 265-327
- [25] Bakır, E.; Çal, T.; Aydın Dilsiz, S.; Canpınar, H.; Eken, A.; Ündeğer Bucurgat, Ü. Assessment of the cytotoxic, genotoxic, and apoptotic potential of flurbiprofen in HeLa and HepG2 cell lines. *J. Biochem. Mol. Toxicol.* **2021**, *35*, 1-11.
- [26] Tan, J.; Li, C.; Wang, Q.; Li, S.; Chen, S.; Zhang, J.; Wang, P.C.; Ren, L.; Liang, X.J. A carrier-free nanostructure based on platinum(IV) prodrug enhances cellular uptake and cytotoxicity. *Mol. Pharm.* **2018**, *15*, 1724-1728.
- [27] Wang, X.; Ye, X.; Zhang, Y.; Ji, F. Flurbiprofen suppresses the inflammation, proliferation, invasion and migration of colorectal cancer cells via COX2. *Oncol. Lett.* **2020**, *20*, 132, doi: 10.3892/ol.2020.11993.
- [28] Çıkla, P.; Tatar, E.; Küçükgülzel, İ.; Şahin, F.; Yurdakul, D.; Basu, A.; Krishnan, R.; Nichols, D.B.; Kaushik-Basu, N.; Küçükgülzel, S.G. Synthesis and characterization of flurbiprofen hydrazide derivatives as potential anti-HCV, anticancer and antimicrobial agents. *Med. Chem. Res.* **2013**, *22*, 5685–5699.
- [29] Aydın, S.; Kaushik-Basu, N.; Arora, P.; Basu, A.; Nichols, D.B.; Talele, T.T.; Akkurt, M.; Çelik, İ.; Büyükgüngör, O.; Küçükgülzel, S.G. Microwave assisted synthesis of some novel flurbiprofen hydrazidehydrazones as anti-HCV NS5B and anticancer agents. *Marmara Pharm. J.* **2013**, *17*, 26–34.

- [30] Alam, A.; Ali, M.; Ur Rehman, N.; Ullah, S.; Halim, S.A.; Latif, A.; Zainab,; Khan, A.; Ullah, O.; Ahmad, S. *et al.*; Bio-oriented synthesis of novel (S)-flurbiprofen clubbed hydrazone schiff's bases for diabetic management: In vitro and in silico studies. *Pharmaceuticals* **2022**, *15*, 672.
- [31] Zaheer, M.; Zia-Ur-Rehman, M.; Jamil, N.; Arshad, M.N.; Siddiqui, S.Z.; Asiri, A.M. Efficient green synthesis of *N*'-benzylidene-2-(2-fluorobiphenyl) propanehydrazides: Crystal structure and anti-oxidant potential. *J. Chem. Res.* **2015**, *39*, 668–673.
- [32] Kulabaş, N.; Özakpınar, Ö.B.; Özsavcı, D.; Leyssen, P.; Neyts, J.; Küçükgülzel, İ. Synthesis, characterization and biological evaluation of thioureas, acylthioureas and 4-thiazolidinones as anticancer and antiviral agents. *Marmara Pharm. J.* **2017**, *21*, 371–384.
- [33] Wyrzykiewicz, E.; Prukala, D. New isomeric N-substituted hydrazones of ortho, meta and para hydroxybenzaldehydes. *Pol. J. Chem.* **1998**, *72*, 694–702.
- [34] Patorski, P.; Wyrzykiewicz, E.; Bartkowiak, G. Synthesis and conformational assignment of *N*-(E)-stilbenyloxymethylenecarbonyl-substituted hydrazones of acetone and o-(m-and p-) chloro- (nitro-) benzaldehydes by means of ¹H and ¹³C NMR spectroscopy. *J. Spectrosc.* **2013**, Article ID 197475.
- [35] Demir-Yazici, K.; Güzel-Akdemir, Ö. Synthesis and potential antitumor activities of mandelic acid linked 2-aryl-1,3-thiazolidin-4-ones. *J. Res. Pharm.* **2022**, *26*, 931–940.
- [36] Tatar, E.; Küçükgülzel, İ.; Ötük, G.; Bılgın, M.; De Clercq, E.; Andrei, G.; Soneck, R.; Pannecouque, C.; Kaushik-Basu, N. Synthesis, characterization and biological evaluation of 1,3-thiazolidine-4-ones derived from (2S)-2-benzoylamino-3-methylbutanohydrazide hydrazones. *J. Res. Pharm.* **2021**, *25*, 507–518.

A C G
publications

© 2023 ACG Publications